AFP
IMRX icon

Ausdal Financial Partners’s Immuneering IMRX Stock Holding History

Ausdal Financial Partners’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58K Hold
11,000
– – ﹤0.01% 976
2025
Q4 		$72.4K Buy
+11,000
New +$70.6K ﹤0.01% 930

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ausdal Financial Partners's IMRX Position: Q1 2026 in Review

Ausdal Financial Partners held its Immuneering (IMRX) position steady in Q1 2026 at 11,000 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Ausdal Financial Partners first reported a position in IMRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $72.4K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Ausdal Financial Partners held 11,000 shares of Immuneering worth $58K as of Q1 2026.
  • Ausdal Financial Partners left its Immuneering share count unchanged in Q1 2026.
  • Immuneering made up ﹤0.01% of Ausdal Financial Partners's portfolio in Q1 2026, its #976 holding.
  • Ausdal Financial Partners first reported a position in Immuneering in Q4 2025 and has held it in 2 quarters since.
  • Ausdal Financial Partners's Immuneering position peaked at $72.4K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.